ICER Will Assess Real World Evidence On Accelerated Approvals After Two Years

06 Feb 2020

Process will incorporate real world evidence into future cost effectiveness updates of already reviewed drugs to supplement the information available prior to launch.

REAL Letters in box — ICER Responds To Requests To Use More RWE In Assessments

The Institute for Clinical and Economic Review will begin a pilot program this year to generate new real world evidence on prescription drugs approved by the US Food and Drug Administration under accelerated approval pathways.

The pilot will “explore how best to develop and assess new RWE as a cornerstone” of the group’s process for...